OISIN BIOTECHNOLOGIES
Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age-related diseases. It is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces the negative effects of aging pathologies and also extends the median lifespan and survival. Oisin Biotechnologies was founded in 2014 and is headquartered in Seattle, Washington.
OISIN BIOTECHNOLOGIES
Social Links:
Industry:
Biopharma Biotechnology Medical
Founded:
2014-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.oisinbio.com
Total Employee:
11+
Status:
Active
Contact:
206-880-1166
Total Funding:
7.12 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Content Delivery Network Global Site Tag JQuery CDN Typekit Squarespace
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Investors List
Althea Ventures
Althea Ventures investment in Seed Round - Oisin Biotechnologies
Benjamin Kong
Benjamin Kong investment in Seed Round - Oisin Biotechnologies
Kingsley Advani
Kingsley Advani investment in Seed Round - Oisin Biotechnologies
Avant Global
Avant Global investment in Seed Round - Oisin Biotechnologies
Hedgewood
Hedgewood investment in Seed Round - Oisin Biotechnologies
KIZOO Technology Capital
KIZOO Technology Capital investment in Seed Round - Oisin Biotechnologies
Newest Events participated
Official Site Inspections
http://www.oisinbio.com
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Oisin Biotechnologies" on Search Engine
Oisín Biotechnologies
Jul 24, 2017 Today Oisín Biotechnologies is working to make the myth a reality. Reality. Oisín Biotechnologies' ground-breaking research and technology is demonstrating that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself. We invite you to see how.See details»
Oisin Biotechnologies - Crunchbase Company Profile & Funding
Oisin Biotechnologies is a drug development company focused on mitigating the senolytic technology to combat age-related diseases. Seattle, Washington, United States. 11-50. Seed. Private. www.oisinbio.com. 39,901. Total Funding Amount. Unlock for free. Contacts 8. Employee Profiles 3. Investors 6. Similar Companies 7.See details»
Oisin Biotechnologies | LinkedIn
Oisin Biotechnologies | 1,980 followers on LinkedIn. Using using senolytic technology to combat age-related diseases. | Oisin Biotechnologies is a longevity therapeutics platform company...See details»
Oisín Biotechnologies Raises Seed Funding to Advance ā¦
May 27, 2021 SEATTLE-- ( BUSINESS WIRE )--Oisín Biotechnologies, a privately held, preclinical biotechnology company focused on mitigating the effects of age-related diseases, today announced it has...See details»
The quest to turn back the clock - Nature
Dec 1, 2023 At the preclinical stage, Seattle, US-based Oisin Biotechnologies, established in 2014, is targeting senescent cells through p16, a protein involved in cell cycle regulation that is highly...See details»
Oisin Biotechnologies Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Oisin Biotechnologies. Use the PitchBook Platform to explore the full profile.See details»
Oisín Announces $5 Million in New Seed Funding | Lifespan.io
May 27, 2021 ADVERTISEMENT. SEATTLE ā May 27, 2021 ā Oisín Biotechnologies, a privately held, preclinical biotechnology company focused on mitigating the effects of age-related diseases, today announced it has completed an oversubscribed round raising $5 million in new seed funding. Led by early-stage investing firm Althea Group, LLC, the ā¦See details»
Oisin Biotechnologies - Funding, Financials, Valuation & Investors
Oisin Biotechnologies has raised a total of. $7.1M. in funding over 4 rounds. Their latest funding was raised on May 27, 2021 from a Seed round. Oisin Biotechnologies is funded by 6 investors. Althea Ventures and Benjamin Kong are ā¦See details»
Oisín Biotechnologies Raises Seed Funding to Advance ... - BioSpace
May 27, 2021 SEATTLE-- ( BUSINESS WIRE )-- Oisín Biotechnologies, a privately held, preclinical biotechnology company focused on mitigating the effects of age-related diseases, today announced it has completed an oversubscribed round raising $5 million in new seed funding. Led by early-stage investing firm Althea Group, LLC, the round brings Oisínās ...See details»
Oisín Biotechnologies Included in - Business Wire
Feb 26, 2020 SEATTLE-- ( BUSINESS WIRE )--Oisín Biotechnologies, a privately held, preclinical biotechnology company focused on mitigating the effects of age-related diseases, today announced that...See details»
Oisin Biotechnologies Company Profile - Craft
Overview. Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat age-related diseases. It develops a DNA-targeted intervention to clear senescent cells. The company aims to reduce negative effects of aging pathologies and extend median lifespan and survival. Type. Private. Status. Active. Founded. 2014. HQ.See details»
An Update on the Work of Oisin Biotechnologies: Building ā¦
Jun 5, 2017 The initial goal of development at Oisin Biotechnologies is the targeted destruction of senescent cells, a path to produce one of the first working rejuvenation therapies to follow the SENS model of treating aging through damage repair.See details»
Oisìn Biotechnologies Raises $5M in Seed Funding - FinSMEs
USA. Published on May 27, 2021. Oisìn Biotechnologies, a Seattle WA-based company that specializes in mitigating the effects of age-related diseases, raised $5M in seed funding. The round,...See details»
Longevity senotherapeutics report: Oisín ā tackling senescence
Jul 12, 2021 Founded in 2014, Oisín Biotechnologies is a platform drug development company that had an initial goal of producing a senolytic platform that could kill senescent cells without using toxic drugs and causing significant collateral damage.See details»
Oisin Biotechnologies | VentureRadar
Oisin Biotechnologies | VentureRadar. Location: USA. Founded in 2014. Private Company. Develops a patent-pending, DNA-targeted intervention to clear senescent cells, reducing negative effects of aging pathologies and extending median lifespan and survival.See details»
Plasmid based senolytics from Oisín Biotechnologies - lifespan
Summary. Oisin Biotechnologies is a rejuvenation biotechnology company that received its seed funding from the Methuselah Foundation and SENS Research Foundation a few years ago. The current focus of Oisin is the targeted clearance of senescent cells using drugs known as senolytics.See details»
VitaDAO - Oisín Biotechnologies - Pioneering Genetic Medicines ā¦
Oisín Biotechnologies is a multi-asset longevity biotech company pioneering genetic medicines to combat sarcopenia and other age-related diseases to promote healthier, longer lives. Funding. $50,000. Initiated. 9.10.2023. Approval. 86.47% Voted Yes. Oisín site. Matthew Scholz. CEO & Co-founder. Dr. John Lewis. Chief Science Officer.See details»
Entos and Oisin Bio Launch OncoSenX: A Spinoff Company
Oisín Biotechnologies is a senescence-focused biotechnology company. Their ground-breaking research and technology demonstrate that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself. Matthew Scholz is the CEO of Oisin and the Chairman and CEO of OncoSenX.See details»
Oisin Biotechnologies - Contacts, Employees, Board Members, ā¦
Oisin Biotechnologies is a drug development company focused on mitigating the senolytic technology to combat age-related diseases.See details»
Oisin Biotechnologies | Lifespan.io
Oisin Biotechnologies | Lifespan.io. Oisin Biotechnologies are developing a plasmid-based approach to destroying senescent and cancer cells. This approach may allow for higher selectivity when compared to drug approaches and could reduce side effects too.See details»